Research
AR1001 slowed Alzheimer’s decline in one trial group but not overall
AR1001 slowed decline by 31% in 604 patients not taking other Alzheimer’s drugs, but the overall trial result was not statistically significant.

AR1001, a pill in the same family of medicines as Viagra, showed mixed results in people with early Alzheimer’s disease in the phase III POLARIS-AD trial, MedPage Today reported. The trial included 1,535 patients overall. At 52 weeks, the difference versus placebo in the overall group was -0.11 points on a measure of cognitive and functional impairment, which was not statistically significant (P=0.4015).
Among 604 patients not taking an acetylcholinesterase inhibitor or memantine at baseline, the treatment difference versus placebo was -0.44 points (P=0.0266), representing a 31% slowing of decline, MedPage Today reported. Diarrhea, falls and dizziness were the most frequent adverse events. The Guardian reported that experts called for further trials and said the drug would need regulatory review before it could be prescribed for Alzheimer’s.


